Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice

نویسندگان

  • Haiqing Ma
  • Saradhi Mallampati
  • Gang An
  • Jin Wang
چکیده

1Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China 2Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China 4Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antibiotic resistance status and its costs in hematological patients: A two-year analysis

Background: Most frequently, empirical antibiotic therapy is immediately administered for patients with febrile neutropenia (FN). In this study, its aim was to assess the antibiotic resistance status and the cost of antibacterial agents in FN patients associated with hematological malignancies. Methods: The cost of antibacterial agents used in FN episodes in patients with hematologic neoplasms ...

متن کامل

CAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens

Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...

متن کامل

Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.

The high remission rates observed in patients with chronic myelogenous leukemia who receive Imatinib mesylate (Gleevec) indicate that targeted therapy for hematological malignancies is achievable. At the same time, progress in cellular biology over the past decade has resulted in a better understanding of the process of malignant transformation, a better classification of subtypes of each disea...

متن کامل

Monoclonal antibodies in hematological malignancies: past, present and future.

Much progress has been made during the last few decades in the treatment of hematological malignancies. Monoclonal antibodies (MoAbs) represent a major advance toward a targeted therapy that can dramatically improve the antitumor effect with a substantial reduction of toxicity derived from therapy. Unlike many small molecules, MoAbs offer unique target specificity. Several MoAbs are now in clin...

متن کامل

Determination of Serologic and Molecular Prevalence of Hepatitis Type B, C, and G Infections in Patients with Hematological Malignancy in the South of Fars Province, Iran

Background & Objectives: Hepatitis type G virus (HGV) is a flavivirus with RNA genome which has high nucleotide and amino acid similarity with HCV. HGV can infect blood lymphocytes for long period and may have role in inducing or complicating the clinical outcomes in patients with hematological malignancies. Therefore in this study the prevalence of HGV, HCV, and HBV infections were evaluated i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2015  شماره 

صفحات  -

تاریخ انتشار 2015